IN2014KN02423A - - Google Patents
Info
- Publication number
- IN2014KN02423A IN2014KN02423A IN2423KON2014A IN2014KN02423A IN 2014KN02423 A IN2014KN02423 A IN 2014KN02423A IN 2423KON2014 A IN2423KON2014 A IN 2423KON2014A IN 2014KN02423 A IN2014KN02423 A IN 2014KN02423A
- Authority
- IN
- India
- Prior art keywords
- present
- compounds
- abc
- cftr
- transporters
- Prior art date
Links
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 abstract 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 abstract 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79045906P | 2006-04-07 | 2006-04-07 | |
PCT/US2007/008975 WO2007117715A2 (en) | 2006-04-07 | 2007-04-09 | Modulators of atp-binding cassette transporters |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014KN02423A true IN2014KN02423A (sl) | 2015-05-01 |
Family
ID=38477342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2423KON2014 IN2014KN02423A (sl) | 2006-04-07 | 2007-04-09 |
Country Status (22)
Country | Link |
---|---|
US (9) | US7776905B2 (sl) |
EP (5) | EP2007756B1 (sl) |
JP (3) | JP5420395B2 (sl) |
CN (2) | CN101460489A (sl) |
AU (1) | AU2007235260B2 (sl) |
BR (1) | BRPI0710965B8 (sl) |
CA (2) | CA2869945C (sl) |
CY (3) | CY1116979T1 (sl) |
DK (3) | DK2007756T3 (sl) |
ES (4) | ES2882684T3 (sl) |
HU (4) | HUE036165T2 (sl) |
IL (1) | IL194576A (sl) |
IN (1) | IN2014KN02423A (sl) |
LT (1) | LT3091011T (sl) |
MX (1) | MX2008012945A (sl) |
NZ (3) | NZ596889A (sl) |
PL (4) | PL3327016T3 (sl) |
PT (3) | PT2674428T (sl) |
RU (1) | RU2451018C2 (sl) |
SI (4) | SI3327016T1 (sl) |
WO (1) | WO2007117715A2 (sl) |
ZA (1) | ZA200809290B (sl) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
EP1664006A2 (en) | 2003-09-06 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
RU2006120549A (ru) * | 2003-11-14 | 2007-12-27 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ (Us) | Š¢ŠøŠ°Š·Š¾Š»Ń Šø Š¾ŠŗŃŠ°Š·Š¾Š»Ń, ŠæŃŠøŠ¼ŠµŠ½ŃŠµŠ¼ŃŠµ Š² ŠŗŠ°ŃŠµŃŃŠ²Šµ Š¼Š¾Š“ŃŠ»ŃŃŠ¾ŃŠ¾Š² ŃŃŠ°Š½ŃŠæŠ¾ŃŃŠµŃŠ¾Š² Š°ŃŃ-ŃŠ²ŃŠ·ŃŠ²Š°ŃŃŠµŠ¹ ŠŗŠ°ŃŃŠµŃŃ |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
WO2005075435A1 (en) * | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
CA2810655C (en) | 2004-06-24 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
EP1912983B1 (en) | 2005-08-11 | 2011-06-08 | Vertex Pharmaceuticals, Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
SI2395002T1 (sl) * | 2005-11-08 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavek, vsebujoÄ heterocikliÄni modulator prenaÅ”alcev z ATP-vezavno kaseto |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
EP3708564A1 (en) | 2005-12-28 | 2020-09-16 | Vertex Pharmaceuticals Incorporated | A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CN103214450B (zh) * | 2005-12-28 | 2016-10-05 | å¼ē¹å ęÆčÆåęéå ¬åø | ä½äøŗatp-ē»åēč½¬čæčē½č°čåē1-(čÆ并[d][1,3]é“äŗę°§ęēÆęēÆ-5-åŗ)-n-(čÆåŗ)ēÆäøē·-ē²é °čŗč”ēē© |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
EP2007756B1 (en) | 2006-04-07 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
WO2008127399A2 (en) * | 2006-11-03 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as cftr modulators |
US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
KR20100016073A (ko) * | 2007-04-02 | 2010-02-12 | ģøģ¤ķ°ķķø ķ¬ ģģė ķ¬ģ¤ | ļ¼£ļ½ļ½ļ½ ģµģ ģ ķķ©ė¬¼ ė° ģ“ģ ģ©ė |
JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | ćć¼ćććÆć¹ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗ ć¤ć³ć³ć¼ćć¬ć¤ććć | ļ¼£ļ½ļ½ļ½ć®ć¢ćøć„ć¬ć¼ćæć¼ |
EP2158183A2 (en) * | 2007-05-25 | 2010-03-03 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
CA2696298C (en) | 2007-08-24 | 2016-09-06 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
ES2658064T3 (es) | 2007-11-16 | 2018-03-08 | Vertex Pharmaceuticals Incorporated | Moduladores de isoquinolina de transportadores de casete de uniĆ³n a ATP |
PL2639223T3 (pl) | 2007-12-07 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | SposĆ³b wytwarzania kwasĆ³w cykloalkilokarboksyamido-pirydyno-benzoesowych |
EA201070699A1 (ru) * | 2007-12-07 | 2011-02-28 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | ŠŠ¾Š¼ŠæŠ¾Š·ŠøŃŠøŠø 3-(6-(1-2,2-Š“ŠøŃŃŠ¾ŃŠ±ŠµŠ½Š·Š¾[d][1,3]Š“ŠøŠ¾ŠŗŃŠ¾Š»-5-ŠøŠ»)ŃŠøŠŗŠ»Š¾ŠæŃŠ¾ŠæŠ°Š½ŠŗŠ°ŃŠ±Š¾ŠŗŃŠ°Š¼ŠøŠ“Š¾)-3-Š¼ŠµŃŠøŠ»ŠæŠøŃŠøŠ“ŠøŠ½-2-ŠøŠ»)Š±ŠµŠ½Š·Š¾Š¹Š½Š¾Š¹ ŠŗŠøŃŠ»Š¾ŃŃ |
SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
EP2078711A1 (en) * | 2007-12-28 | 2009-07-15 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor |
CA2931134C (en) | 2008-02-28 | 2019-07-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
EP2980077B1 (en) | 2008-03-31 | 2020-05-06 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as cftr modulators |
WO2009131951A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
US20090264433A1 (en) * | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
WO2009131957A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
US20090270398A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
JP2012503005A (ja) * | 2008-09-19 | 2012-02-02 | ć¤ć³ć¹ćć£ćć„ć¼ć ćć©ć¢ ćÆć³ćÆć¼ć«ć ćć«ć¹ | ć¤ććć¾ć¼ć«čŖå°ä½ććć³ććŖć¢ć¾ć¼ć«čŖå°ä½ćå«ććååē©ćēµęē©ćŖćć³ć«ę¹ę³ć |
WO2010037066A2 (en) | 2008-09-29 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
SI2349263T1 (sl) * | 2008-10-23 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Modulatorji cistiƤÅno-fibroznega transmembranskega regulatorja prevodnosti |
NZ609962A (en) * | 2008-11-06 | 2014-11-28 | Vertex Pharma | Modulators of atp-binding cassette transporters |
UA104876C2 (uk) * | 2008-11-06 | 2014-03-25 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŃŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | ŠŠ¾Š“ŃŠ»ŃŃŠ¾ŃŠø atŃ-Š·Š²'ŃŠ·ŃŠ²Š°Š»ŃŠ½ŠøŃ ŠŗŠ°ŃŠµŃŠ½ŠøŃ ŃŃŠ°Š½ŃŠæŠ¾ŃŃŠµŃŃŠ² |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | ė²ķ ģ¤ ķė§ģķ°ģ¹¼ģ¤ ģøģ½ķ¬ė ģ“ķ°ė | ėģ± ģ¬ģ ģ¦ ė§ķ”ėØ ģ ėė ģ”°ģ ģģ ģ”°ģ ģģ ģ ģ”° ė°©ė² |
US8511216B2 (en) * | 2009-03-30 | 2013-08-20 | Kanzaki Kokyukoki Mfg. Co., Ltd. | Hydraulic actuator unit |
US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
US8497271B2 (en) | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
EP2813227A1 (en) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
ES2604105T3 (es) * | 2010-03-25 | 2017-03-03 | Vertex Pharmaceuticals Incorporated | Formula cristalina de (r) -1 (2,2- difluorobenzo [d] [1,3] dioxol - 5yl) - n- (1- (2,3 - dihidroxipropil) - 6 - fluoro - 2- (1 - hydroxy-2-metilpropan-2il) -1h-indol-5il) cyclopropanecarboxamida |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
CN102933206A (zh) | 2010-04-07 | 2013-02-13 | å¼ē¹å ęÆčÆåęéå ¬åø | 3-(6-(1-(2ļ¼2-äŗę°čÆ并[d][1ļ¼3]äŗę°§ęēÆęēÆ-5-åŗ)ēÆäøē·ē²é °čŗåŗ)-3-ē²åŗå”å¶-2-åŗ)čÆē²é øēåŗä½å½¢å¼ |
JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | ćć¼ćććÆć¹ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗ ć¤ć³ć³ć¼ćć¬ć¤ććć | ļ¼āļ¼ļ¼āļ¼ļ¼āļ¼ļ¼ļ¼ļ¼āćøćć«ćŖććć³ć¾ļ¼»ļ½ļ¼½ļ¼»ļ¼ļ¼ļ¼ļ¼½ćøćŖćć½ć¼ć«āļ¼āć¤ć«ļ¼ć·ćÆććććć³ć«ć«ćććµććļ¼āļ¼āć”ćć«ććŖćøć³āļ¼āć¤ć«ļ¼å®ęÆé¦é øć®å»č¬ēµęē©ććć³ćć®ęäø |
WO2011133956A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
CA2796602A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
AU2011242452A1 (en) * | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
MX342288B (es) | 2010-04-22 | 2016-09-23 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
NZ603386A (en) | 2010-05-20 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions and administrations thereof |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
RU2013112937A (ru) * | 2010-08-23 | 2014-09-27 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | Š¤Š°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠµŃŠŗŠøŠµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøŃŠøŠø (r)-1-(2, 2-Š“ŠøŃŃŠ¾ŃŠ±ŠµŠ½Š·Š¾[d][1, 3]Š“ŠøŠ¾ŠŗŃŠ¾Š»-5-ŠøŠ»)-n-(2, 3-Š“ŠøŠ³ŠøŠ“ŃŠ¾ŠŗŃŠøŠæŃŠ¾ŠæŠøŠ»)-6-ŃŃŠ¾Ń-2-(1-Š³ŠøŠ“ŃŠ¾ŠŗŃŠø-2-Š¼ŠµŃŠøŠ»ŠæŃŠ¾ŠæŠ°Š½-2-ŠøŠ»)-1Š½-ŠøŠ½Š“Š¾Š»-5-ŠøŠ»)ŃŠøŠŗŠ»Š¾ŠæŃŠ¾ŠæŠ°Š½ŠŗŠ°ŃŠ±Š¾ŠŗŃŠ°Š¼ŠøŠ“Š° Šø ŠøŃ ŠæŃŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ |
CN102133402B (zh) * | 2011-03-24 | 2013-06-12 | é¦é½å»ē§å¤§å¦éå±åäŗ¬åä»å»é¢ | åę§ēŗ¤ē»“åč·Øčč½¬åƼč°čå åęå¶ååØå¶å¤ę²»ēē³å°æē čÆē©äøēåŗēØ |
EP2773349A1 (en) | 2011-11-02 | 2014-09-10 | Vertex Pharmaceuticals Incorporated | Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases |
IN2014KN00885A (sl) * | 2011-11-08 | 2015-10-02 | Vertex Pharma | |
CN104470518A (zh) | 2012-02-27 | 2015-03-25 | ę²ę³°å ęÆčÆē©č”份ęéå ¬åø | čÆē©ē»åē©åå ¶ę½ēØ |
US8703953B2 (en) | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CA2873214C (en) | 2012-05-11 | 2021-02-16 | Reset Therapeutics, Inc. | Carbazole-containing sulfonamides as cryptochrome modulators |
EP2858645A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
US9012496B2 (en) | 2012-07-16 | 2015-04-21 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
CN102816104B (zh) * | 2012-08-30 | 2014-05-21 | ęµę±å¤§å¦ | äøē§3-ę°°åŗå²åē±»ååē©ēåęę¹ę³ |
ITMI20122065A1 (it) | 2012-12-03 | 2014-06-04 | Univ Padova | Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato |
EP2958924B1 (en) | 2013-02-22 | 2016-12-28 | Bristol-Myers Squibb Company | 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1) |
WO2015006100A1 (en) | 2013-07-08 | 2015-01-15 | Bristol-Myers Squibb Company | Aryl amide kinase inhibitors |
RU2016122882A (ru) | 2013-11-12 | 2017-12-19 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | Š”ŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃŃŠµŠ½ŠøŃ ŃŠ°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠµŃŠŗŠøŃ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøŃŠøŠ¹ Š“Š»Ń Š»ŠµŃŠµŠ½ŠøŃ Š¾ŠæŠ¾ŃŃŠµŠ“Š¾Š²Š°Š½Š½ŃŃ cftr Š·Š°Š±Š¾Š»ŠµŠ²Š°Š½ŠøŠ¹ |
TWI690521B (zh) | 2014-04-07 | 2020-04-11 | ē¾ååę„č£½č„å ¬åø | ä½ēŗé±č±č²ē“ čŖæēÆåä¹å«ęååä¹éÆčŗé”ćčŗåŗē²é øé Æé”åč²é” |
CN103922934B (zh) * | 2014-04-11 | 2016-03-30 | åäŗ¬ä¹åØę³°å å»čÆęęÆęéå ¬åø | ę“»ę³¼äŗē²åŗååē©ēē·åŗåę¹ę³ |
ES2957761T3 (es) | 2014-04-15 | 2024-01-25 | Vertex Pharma | Composiciones farmacĆ©uticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quĆstica |
RU2020134082A (ru) | 2014-10-06 | 2020-11-27 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | ŠŠ¾Š“ŃŠ»ŃŃŠ¾ŃŃ ŃŠµŠ³ŃŠ»ŃŃŠ¾ŃŠ° ŃŃŠ°Š½ŃŠ¼ŠµŠ¼Š±ŃŠ°Š½Š½Š¾Š¹ ŠæŃŠ¾Š²Š¾Š“ŠøŠ¼Š¾ŃŃŠø ŠæŃŠø Š¼ŃŠŗŠ¾Š²ŠøŃŃŠøŠ“Š¾Š·Šµ |
JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | ćć¼ćććÆć¹ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗ ć¤ć³ć³ć¼ćć¬ć¤ćććļ¼¶ļ½ ļ½ļ½ļ½ ļ½ ļ¼°ļ½ļ½ļ½ļ½ļ½ļ½ļ½ ļ½ļ½ļ½ļ½ļ½ļ½ļ½ ļ¼©ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ ļ½ | å¢čę§ē·ē¶ēčč²«éć³ć³ććÆćæć³ć¹å¶å¾”å åć®ć¢ćøć„ć¬ć¼ćæć¼ć®å ±ēµę¶ |
CA3191010A1 (en) * | 2014-10-31 | 2016-05-06 | AbbVie Global Enterprises Ltd. | Substituted chromanes and method of use |
RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | Š”ŠæŠ¾ŃŠ¾Š± ŠæŃŠ¾Š²ŠµŠ“ŠµŠ½ŠøŃ Š²ŃŃŠ¾ŠŗŠ¾ŠæŃŠ¾ŠøŠ·Š²Š¾Š“ŠøŃŠµŠ»ŃŠ½Š¾Š¹ ŃŠµŃŃŠ¾Š²Š¾Š¹ Š²ŃŃŠ¾ŠŗŠ¾ŃŃŃŠµŠŗŃŠøŠ²Š½Š¾Š¹ Š¶ŠøŠ“ŠŗŠ¾ŃŃŠ½Š¾Š¹ Ń ŃŠ¾Š¼Š°ŃŠ¾Š³ŃŠ°ŃŠøŠø |
WO2016160945A1 (en) | 2015-03-31 | 2016-10-06 | Concert Pharmaceuticals, Inc. | Deuterated vx-661 |
EP3292124B1 (en) | 2015-04-10 | 2019-05-22 | Bristol-Myers Squibb Company | 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors |
CN105153105B (zh) * | 2015-08-15 | 2018-01-19 | ęµę±ę°øå®čÆäøč”份ęéå ¬åø | 1ā(2,2āäŗę°čÆ并[d][1,3]äŗę°§ęēÆęēÆā5āåŗ)ēÆäøē·ē²é øēåęę¹ę³åå ¶äøé“ä½ |
SI3519401T1 (sl) | 2016-09-30 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Modulator regulatorja transmembranske prevodnosti pri cistiÄni fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja |
DK3551622T3 (da) | 2016-12-09 | 2020-11-23 | Vertex Pharma | Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensƦtninger, behandlingsfremgangsmƄder og fremgangsmƄde til fremstilling af modulatoren |
EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AR112467A1 (es) | 2017-08-02 | 2019-10-30 | Vertex Pharma | Procesos para preparar compuestos |
AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
EP3709986B1 (en) | 2017-11-14 | 2023-11-01 | Merck Sharp & Dohme LLC | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
CN111344287B (zh) | 2017-11-14 | 2023-12-19 | é»ę²äøęéč“£ä»»å ¬åø | ä½äøŗå²åčŗ2ļ¼3-åå ę°§é ¶(ido)ęå¶åēę°åå代ēčč³åŗååē© |
MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | ē¾åē¶ę³°å ęÆč£½č„å ¬åø | ēØę¼ę²»ēåč «ēŗåēä¹é«č„ēµåē© |
LT3752510T (lt) | 2018-02-15 | 2023-04-11 | Vertex Pharmaceuticals Incorporated | Makrocikliniai junginiai kaip cistinÄs fibrozÄs transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinÄs kompozicijos, jų panaudojimas cistinÄs fibrozÄs gydymui ir jų gamybos bÅ«das |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
RS65335B1 (sr) | 2018-10-05 | 2024-04-30 | Annapurna Bio Inc | Jedinjenja i kompozicije za leÄenje stanja povezanih sa aktivnoÅ”cĢu receptora apj |
CN109880090A (zh) * | 2019-02-18 | 2019-06-14 | åē (ä½å±±)ēŗ³ē±³ęęęéå ¬åø | äøē§å«ē³å¢ØēÆ仄åē¢³ēŗ³ē±³ē®”ēčé °äŗčŗåƼēęęćåƼēčåå ¶å¶å¤ę¹ę³ |
JP2022544383A (ja) | 2019-08-14 | 2022-10-18 | ćć¼ćććÆć¹ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗ ć¤ć³ć³ć¼ćć¬ć¤ććć | ļ¼£ļ½ļ½ļ½ć¢ćøć„ć¬ć¼ćæć®ēµę¶å½¢ę |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | ē¾åē¶ę³°å ęÆč£½č„å ¬åø | åč «ēŗē¶åč·Øčå³å°čŖæēÆčē½ä¹čŖæēÆå |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | ē¾åē¶ę³°å ęÆč£½č„å ¬åø | č£½åcftrčŖæēÆåä¹ę¹ę³ |
CN113748716B (zh) * | 2020-03-31 | 2022-10-28 | åäøŗęęÆęéå ¬åø | å°åŗęē“¢ēę¹ę³ćč£ ē½®åē³»ē» |
BR112023002651A2 (pt) | 2020-08-20 | 2023-04-04 | Univ Leland Stanford Junior | MĆ©todos de tratamento de doenƧas respiratĆ³rias definidas por hipersecreĆ§Ć£o de muco |
CN112851493B (zh) * | 2020-11-10 | 2022-09-06 | å°å·č»ęēē©ē§ęęéå ¬åø | äøē§2,4,5-äøę°čÆä¹é øēå¶å¤ę¹ę³ |
DE102021207925A1 (de) * | 2021-07-23 | 2023-01-26 | Continental Reifen Deutschland Gmbh | Verbindung, Verfahren zu deren Herstellung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Ozonschutzmittel und/oder Farbstoff |
WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
WO2024056791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
CN115872895A (zh) * | 2023-02-22 | 2023-03-31 | åäŗ¬čÆŗē¦¾č“ęŗē§ęč”份ęéå ¬åø | ēØäŗč”ēēé¾ččŖé øę ååä½äøŗå ę ēéę čÆååå ¶å¶å¤ę¹ę³ćåŗēØ |
Family Cites Families (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5328173A (en) | 1976-08-06 | 1978-03-16 | Zenyaku Kogyo Kk | Novel phenylmethanenitro compound and its preparation |
US4138397A (en) | 1978-02-27 | 1979-02-06 | Richardson-Merrell Inc. | 6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives |
GB8524157D0 (en) * | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
JPS61103861A (ja) | 1984-10-27 | 1986-05-22 | Nitto Kasei Kk | ć¢ćŖāć«ē½®ęć·ć¢ć³é ¢é øćØć¹ćć«ć®č£½é ę¹ę³ |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
GB9005014D0 (en) * | 1990-03-06 | 1990-05-02 | Janssen Pharmaceutica Nv | N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
GB9317764D0 (en) | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
US5510379A (en) | 1994-12-19 | 1996-04-23 | Warner-Lambert Company | Sulfonate ACAT inhibitors |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
WO1998047868A1 (en) | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists |
ES2247707T3 (es) | 1997-06-21 | 2006-03-01 | Roche Diagnostics Gmbh | Derivados del acido barbiturico con actividad antimetastasica y antitumoral. |
ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
US6426331B1 (en) | 1998-07-08 | 2002-07-30 | Tularik Inc. | Inhibitors of STAT function |
EP1035115B1 (en) | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
WO2001019830A1 (en) | 1999-09-10 | 2001-03-22 | Novo Nordisk A/S | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
IT1315267B1 (it) | 1999-12-23 | 2003-02-03 | Novuspharma Spa | Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale |
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
BR0109050A (pt) * | 2000-03-09 | 2004-04-27 | Ono Pharmaceutical Co | Derivados de indol, processo para prepapaĆ§Ć£o e uso dos mesmos |
DE10038019A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Substituierte Triazolopyrid(az)ine |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6562989B2 (en) | 2000-08-07 | 2003-05-13 | Yale University | Catalyst for aromatic CāO, CāN, and CāC bond formation |
TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
AR030357A1 (es) | 2000-08-18 | 2003-08-20 | Lundbeck & Co As H | Derivados 4 -, 5 -, 6 - y 7-indol |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
EP1383799A4 (en) | 2001-04-10 | 2008-08-06 | Transtech Pharma Inc | PROBES, SYSTEMS AND METHODS FOR DISCOVERING MEDICAMENTS |
ATE449763T1 (de) | 2001-04-16 | 2009-12-15 | Eisai R&D Man Co Ltd | 1h-indazolverbindungen die jnk hemmen |
KR100575944B1 (ko) * | 2001-06-28 | 2006-05-02 | ķģ“ģ ķė”ėģø ģøģ½ķ¬ė ģ“ķ°ė | ėÆøģģ²“ ķøė¦¬źøė¦¬ģøė¼ģ“ė ģ ė¬ ėØė°±ģ§(ļ½ļ½ļ½) ė°/ėėģķ¬ģ§ė°©ėØė°±ģ§ ļ½(ļ½ļ½ļ½ ļ½)ė¶ė¹ģ ģµģ ģ ė”ģģķøė¦¬ģėÆøė-ģ¹ķė ģøė, ė²¤ģ”°ķøė ė° ė²¤ģ”°ķ°ģ¤ķ |
WO2003007945A1 (en) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US20030171411A1 (en) | 2001-12-21 | 2003-09-11 | Kodra Janos Tibor | Amide derivatives as therapeutic agents |
AU2003252478A1 (en) | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
TWI244393B (en) | 2002-08-06 | 2005-12-01 | Idenix Pharmaceuticals Inc | Crystalline and amorphous forms of beta-L-2'-deoxythymidine |
US20060083784A1 (en) | 2002-08-07 | 2006-04-20 | Smithkline Beecham Corporation | Amorphous pharmaceutical compositions |
EA009847B1 (ru) | 2002-09-30 | 2008-04-28 | ŠŠ·Šµ Š ŠøŠ“Š¶ŠµŠ½ŃŃ ŠŃ ŠŠ·Šµ Š®Š½ŠøŠ²ŠµŃŃŠøŃŠø ŠŃ ŠŠ°Š»ŠøŃŠ¾ŃŠ½ŠøŃ | ŠŠ½Š³ŠøŠ±ŠøŃŠ¾ŃŃ Š±ŠµŠ»ŠŗŠ°-ŃŠµŠ³ŃŠ»ŃŃŠ¾ŃŠ° ŃŃŠ°Š½ŃŠ¼ŠµŠ¼Š±ŃŠ°Š½Š½Š¾Š¹ ŠæŃŠ¾Š²Š¾Š“ŠøŠ¼Š¾ŃŃŠø ŠæŃŠø Š¼ŃŠŗŠ¾Š²ŠøŃŃŠøŠ“Š¾Š·Šµ Šø ŠøŃ ŠæŃŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ |
JP2004131393A (ja) | 2002-10-08 | 2004-04-30 | Kowa Co | ęęŗ¶åŗę§č£½å¤ |
JP4227389B2 (ja) * | 2002-10-09 | 2009-02-18 | ęµę¾ććććÆć¹ę Ŗå¼ä¼ē¤¾ | ę®åč£ ē½®åć³ćć®č£½é ę¹ę³ |
US20050215614A1 (en) * | 2002-10-15 | 2005-09-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
FR2846327B1 (fr) | 2002-10-25 | 2006-03-24 | Merck Sante Sas | Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant. |
WO2004041277A1 (en) * | 2002-11-01 | 2004-05-21 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
DE10306941A1 (de) | 2003-02-18 | 2004-08-26 | Merck Patent Gmbh | Benzofuranoxyethylamine |
US20050113423A1 (en) * | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
MXPA05010444A (es) | 2003-04-03 | 2005-11-04 | Merck Patent Gmbh | Compuestos de carbonilo. |
HUE031794T2 (en) | 2003-04-11 | 2017-08-28 | Ptc Therapeutics Inc | 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment |
US7696244B2 (en) | 2003-05-16 | 2010-04-13 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
EP1646615B1 (en) * | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
AU2004253541B2 (en) | 2003-06-27 | 2010-10-28 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Amphiphilic pyridinium compounds, method of making and use thereof |
NZ544935A (en) * | 2003-08-15 | 2009-08-28 | Lundbeck & Co As H | Cyclopropyl derivatives as NK3 receptor antagonists |
CN1867549B (zh) * | 2003-08-15 | 2011-07-06 | HĀ·éå¾·č“å ęéå ¬åø | ä½äøŗnk3åä½ę®ęåēēÆäøåŗč”ēē© |
EP1664006A2 (en) | 2003-09-06 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
RU2006115602A (ru) * | 2003-10-08 | 2007-11-20 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ (Us) | ŠŠ¾Š“ŃŠ»ŃŃŠ¾ŃŃ ŠæŠµŃŠµŠ½Š¾ŃŃŠøŠŗŠ¾Š² Š°ŃŃ-ŃŠ²ŃŠ·ŃŠ²Š°ŃŃŠøŃ ŠŗŠ°ŃŃŠµŃ |
WO2005037802A1 (ja) | 2003-10-16 | 2005-04-28 | Sankyo Company, Limited | ļ¼ļ¼ć¢ćŖć¼ć«ććŖććøć³čŖå°ä½ |
WO2005040135A1 (ja) | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | ęć¹ćć¬ć¹č¬ććć³ćć®å»č¬ēØé |
RU2006120549A (ru) * | 2003-11-14 | 2007-12-27 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ (Us) | Š¢ŠøŠ°Š·Š¾Š»Ń Šø Š¾ŠŗŃŠ°Š·Š¾Š»Ń, ŠæŃŠøŠ¼ŠµŠ½ŃŠµŠ¼ŃŠµ Š² ŠŗŠ°ŃŠµŃŃŠ²Šµ Š¼Š¾Š“ŃŠ»ŃŃŠ¾ŃŠ¾Š² ŃŃŠ°Š½ŃŠæŠ¾ŃŃŠµŃŠ¾Š² Š°ŃŃ-ŃŠ²ŃŠ·ŃŠ²Š°ŃŃŠµŠ¹ ŠŗŠ°ŃŃŠµŃŃ |
GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
WO2005075435A1 (en) * | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
WO2005074650A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
BRPI0509282A (pt) | 2004-03-30 | 2007-09-18 | Univ California | compostos contendo hidrazida inibidores de cftr e seus usos |
US20050222271A1 (en) | 2004-03-31 | 2005-10-06 | Le Huang | Novel amorphous form of memantine hydrochloride |
WO2005117514A2 (en) | 2004-06-01 | 2005-12-15 | Tm Bioscience Corporation | Method of detecting cystic fibrosis associated mutations |
AU2005251745A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
US20140343098A1 (en) | 2004-06-24 | 2014-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
CA2810655C (en) | 2004-06-24 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US20060000401A1 (en) | 2004-07-01 | 2006-01-05 | Massetti Joseph A | Mooring line storage device |
AU2005269981A1 (en) | 2004-07-02 | 2006-02-09 | Bonck, John A | Tablet for pulsed delivery |
US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
DE102004047254A1 (de) | 2004-09-29 | 2006-04-13 | Merck Patent Gmbh | Carbonylverbindungen |
EP2363129A1 (en) | 2004-10-13 | 2011-09-07 | PTC Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
MX2007010112A (es) | 2005-02-25 | 2007-10-12 | Ono Pharmaceutical Co | Compuesto indol y uso del mismo. |
US8242149B2 (en) * | 2005-03-11 | 2012-08-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
BRPI0608453A2 (pt) | 2005-03-18 | 2009-12-29 | Univ California | compostos tendo atividade na correĆ§Ć£o de processamento de cftr mutante e usos destes |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
SI2348022T1 (sl) | 2005-03-28 | 2013-05-31 | Toyama Chemical Co., Ltd. | Postopek proizvodnje 1-(3-(2-(1-benzotiofen-5-il)etoksi)propil)azetidin-3-ola ali soli le-tega |
ES2390804T3 (es) | 2005-04-08 | 2012-11-16 | Ptc Therapeutics, Inc. | Composiciones de un 1,2,4-oxadiazol oralmente activo para terapia de supresiĆ³n de la mutaciĆ³n sin sentido |
EP1891018B1 (en) | 2005-05-24 | 2011-11-16 | Vertex Pharmaceuticals, Inc. | Modulators of atp-binding cassette transporters |
ZA200802172B (en) | 2005-08-11 | 2009-06-24 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
EP1912983B1 (en) | 2005-08-11 | 2011-06-08 | Vertex Pharmaceuticals, Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
CA2619438A1 (en) | 2005-08-29 | 2007-03-08 | Irwin C. Jacobs | Amorphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino(4,5-b) indole-1-acetamide |
JP2009511494A (ja) | 2005-10-06 | 2009-03-19 | ćć¼ćććÆć¹ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗ ć¤ć³ć³ć¼ćć¬ć¤ććć | ļ¼”ļ½ļ½ēµåć«ć»ćććć©ć³ć¹ćć¼ćæć¼ć®ć¢ćøć„ć¬ć¼ćæć¼ |
US7401405B2 (en) * | 2005-10-11 | 2008-07-22 | Silverbrook Research Pty Ltd | Method of fabricating inkjet nozzles having associated ink priming features |
US20120232059A1 (en) * | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
SI2395002T1 (sl) * | 2005-11-08 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavek, vsebujoÄ heterocikliÄni modulator prenaÅ”alcev z ATP-vezavno kaseto |
US8030305B2 (en) | 2005-12-21 | 2011-10-04 | Janssen Pharmaceutica N.V. | Triazolopyridazines as kinase modulators |
AU2006331614A1 (en) | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of ABC transporters |
EP1974212A1 (en) | 2005-12-27 | 2008-10-01 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
CN103214450B (zh) | 2005-12-28 | 2016-10-05 | å¼ē¹å ęÆčÆåęéå ¬åø | ä½äøŗatp-ē»åēč½¬čæčē½č°čåē1-(čÆ并[d][1,3]é“äŗę°§ęēÆęēÆ-5-åŗ)-n-(čÆåŗ)ēÆäøē·-ē²é °čŗč”ēē© |
EP3708564A1 (en) | 2005-12-28 | 2020-09-16 | Vertex Pharmaceuticals Incorporated | A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
GEP20125378B (en) | 2006-03-20 | 2012-01-10 | Vertex Pharma | Pharmaceutical compositions |
EP2001498A4 (en) | 2006-03-20 | 2013-01-23 | Vertex Pharma | PHARMACEUTICAL COMPOSITIONS |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
EP2007756B1 (en) | 2006-04-07 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
ES2377840T3 (es) * | 2006-05-12 | 2012-04-02 | Vertex Pharmaceuticals, Inc. | Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida |
JP2010507577A (ja) | 2006-10-23 | 2010-03-11 | ćØć¹ćøć¼ćØććÆć¹ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗćć¤ć³ć³ć¼ćć¬ć¤ććć | ććŖć¢ć¾ćććŖććøć³ćæć³ććÆč³Ŗććć¼ć¼ć¢ćøć„ć¬ć¼ćæć¼ |
WO2008127399A2 (en) | 2006-11-03 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as cftr modulators |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
WO2008064259A2 (en) | 2006-11-21 | 2008-05-29 | Biokey, Inc. | Solid dispersion composition comprising fluvastatin |
WO2008065732A1 (fr) | 2006-11-27 | 2008-06-05 | Nippon Polyurethane Industry Co., Ltd. | ProcĆ©dĆ© de production d'un mĆ©lange Ć base d'isocyanate modifiĆ© contenant une liaison allophanate et une liaison isocyanurate |
US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | ćć¼ćććÆć¹ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗ ć¤ć³ć³ć¼ćć¬ć¤ććć | ļ¼£ļ½ļ½ļ½ć®ć¢ćøć„ć¬ć¼ćæć¼ |
CN101687883B (zh) | 2007-05-25 | 2012-05-23 | ę²ę³°å ęÆčÆē©č”份ęéå ¬åø | åę§ēŗ¤ē»“åč·Øčä¼ åƼč°čå åēč°čå |
US20110177999A1 (en) * | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
CA2696298C (en) | 2007-08-24 | 2016-09-06 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP2201010B1 (en) * | 2007-09-14 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP2222304A2 (en) | 2007-09-14 | 2010-09-01 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
ES2658064T3 (es) | 2007-11-16 | 2018-03-08 | Vertex Pharmaceuticals Incorporated | Moduladores de isoquinolina de transportadores de casete de uniĆ³n a ATP |
US8227463B2 (en) | 2007-11-22 | 2012-07-24 | Zenyaku Kogyo Kabushiki Kaisha | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same |
SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
EA201070699A1 (ru) * | 2007-12-07 | 2011-02-28 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | ŠŠ¾Š¼ŠæŠ¾Š·ŠøŃŠøŠø 3-(6-(1-2,2-Š“ŠøŃŃŠ¾ŃŠ±ŠµŠ½Š·Š¾[d][1,3]Š“ŠøŠ¾ŠŗŃŠ¾Š»-5-ŠøŠ»)ŃŠøŠŗŠ»Š¾ŠæŃŠ¾ŠæŠ°Š½ŠŗŠ°ŃŠ±Š¾ŠŗŃŠ°Š¼ŠøŠ“Š¾)-3-Š¼ŠµŃŠøŠ»ŠæŠøŃŠøŠ“ŠøŠ½-2-ŠøŠ»)Š±ŠµŠ½Š·Š¾Š¹Š½Š¾Š¹ ŠŗŠøŃŠ»Š¾ŃŃ |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
PL2639223T3 (pl) | 2007-12-07 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | SposĆ³b wytwarzania kwasĆ³w cykloalkilokarboksyamido-pirydyno-benzoesowych |
EP2231671B1 (en) * | 2007-12-13 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CA2931134C (en) | 2008-02-28 | 2019-07-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
EP2980077B1 (en) * | 2008-03-31 | 2020-05-06 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as cftr modulators |
MX2010011209A (es) | 2008-04-24 | 2010-11-12 | Squibb Bristol Myers Co | Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer. |
EP2328618B1 (en) | 2008-08-13 | 2017-11-29 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4- oxoquinoline-3-carboxamide and administration thereof |
US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
WO2010037066A2 (en) | 2008-09-29 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
SI2349263T1 (sl) | 2008-10-23 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Modulatorji cistiƤÅno-fibroznega transmembranskega regulatorja prevodnosti |
NZ592687A (en) | 2008-10-23 | 2013-04-26 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
NZ592504A (en) * | 2008-10-23 | 2013-04-26 | Vertex Pharma | Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
US20110257223A1 (en) * | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŃŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | ŠŠ¾Š“ŃŠ»ŃŃŠ¾ŃŠø atŃ-Š·Š²'ŃŠ·ŃŠ²Š°Š»ŃŠ½ŠøŃ ŠŗŠ°ŃŠµŃŠ½ŠøŃ ŃŃŠ°Š½ŃŠæŠ¾ŃŃŠµŃŃŠ² |
NZ609962A (en) | 2008-11-06 | 2014-11-28 | Vertex Pharma | Modulators of atp-binding cassette transporters |
US8367660B2 (en) * | 2008-12-30 | 2013-02-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | ė²ķ ģ¤ ķė§ģķ°ģ¹¼ģ¤ ģøģ½ķ¬ė ģ“ķ°ė | ėģ± ģ¬ģ ģ¦ ė§ķ”ėØ ģ ėė ģ”°ģ ģģ ģ”°ģ ģģ ģ ģ”° ė°©ė² |
DK2408749T3 (en) | 2009-03-20 | 2018-08-13 | Vertex Pharma | CYSTIC FIBROSE TRANSMEMBRAN CONDUCTOR CONTROLLER MODULATORS |
KR20120083416A (ko) | 2009-09-17 | 2012-07-25 | ė²ķ ģ¤ ķė§ģķ°ģ¹¼ģ¤ ģøģ½ķ¬ė ģ“ķ°ė | ģģė¹ģķ“ė¦ ķķ©ė¬¼ģ ģ ģ”° ė°©ė² |
EP2813227A1 (en) * | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
CA2778492A1 (en) * | 2009-10-23 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Process for preparing modulators of cystic fibrosis transmembrane conductance regulator |
WO2011050220A1 (en) * | 2009-10-23 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
US8471029B2 (en) * | 2010-03-19 | 2013-06-25 | Vertex Pharmaceutical Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
ES2604105T3 (es) * | 2010-03-25 | 2017-03-03 | Vertex Pharmaceuticals Incorporated | Formula cristalina de (r) -1 (2,2- difluorobenzo [d] [1,3] dioxol - 5yl) - n- (1- (2,3 - dihidroxipropil) - 6 - fluoro - 2- (1 - hydroxy-2-metilpropan-2il) -1h-indol-5il) cyclopropanecarboxamida |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | ćć¼ćććÆć¹ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗ ć¤ć³ć³ć¼ćć¬ć¤ććć | ļ¼āļ¼ļ¼āļ¼ļ¼āļ¼ļ¼ļ¼ļ¼āćøćć«ćŖććć³ć¾ļ¼»ļ½ļ¼½ļ¼»ļ¼ļ¼ļ¼ļ¼½ćøćŖćć½ć¼ć«āļ¼āć¤ć«ļ¼ć·ćÆććććć³ć«ć«ćććµććļ¼āļ¼āć”ćć«ććŖćøć³āļ¼āć¤ć«ļ¼å®ęÆé¦é øć®å»č¬ēµęē©ććć³ćć®ęäø |
CN102933206A (zh) | 2010-04-07 | 2013-02-13 | å¼ē¹å ęÆčÆåęéå ¬åø | 3-(6-(1-(2ļ¼2-äŗę°čÆ并[d][1ļ¼3]äŗę°§ęēÆęēÆ-5-åŗ)ēÆäøē·ē²é °čŗåŗ)-3-ē²åŗå”å¶-2-åŗ)čÆē²é øēåŗä½å½¢å¼ |
MX342288B (es) | 2010-04-22 | 2016-09-23 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
CA2796602A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
WO2011133956A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
AU2011242452A1 (en) * | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
EP2787043B1 (fr) | 2010-04-30 | 2018-03-21 | Total Marketing Services | Utilisation de dƩrivƩs organogelateurs dans des compositions bitumineuses pour amƩliorer leur rƩsistance aux agressions chimiques |
AR081920A1 (es) | 2010-05-20 | 2012-10-31 | Vertex Pharma | Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica |
NZ603386A (en) * | 2010-05-20 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions and administrations thereof |
US8563593B2 (en) * | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
RU2013112937A (ru) | 2010-08-23 | 2014-09-27 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | Š¤Š°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠµŃŠŗŠøŠµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøŃŠøŠø (r)-1-(2, 2-Š“ŠøŃŃŠ¾ŃŠ±ŠµŠ½Š·Š¾[d][1, 3]Š“ŠøŠ¾ŠŗŃŠ¾Š»-5-ŠøŠ»)-n-(2, 3-Š“ŠøŠ³ŠøŠ“ŃŠ¾ŠŗŃŠøŠæŃŠ¾ŠæŠøŠ»)-6-ŃŃŠ¾Ń-2-(1-Š³ŠøŠ“ŃŠ¾ŠŗŃŠø-2-Š¼ŠµŃŠøŠ»ŠæŃŠ¾ŠæŠ°Š½-2-ŠøŠ»)-1Š½-ŠøŠ½Š“Š¾Š»-5-ŠøŠ»)ŃŠøŠŗŠ»Š¾ŠæŃŠ¾ŠæŠ°Š½ŠŗŠ°ŃŠ±Š¾ŠŗŃŠ°Š¼ŠøŠ“Š° Šø ŠøŃ ŠæŃŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ |
RU2013113627A (ru) | 2010-08-27 | 2014-10-10 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | Š¤Š°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠµŃŠŗŠ°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøŃŠøŃ Šø ŠµŠµ Š²Š²ŠµŠ“ŠµŠ½ŠøŃ |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
EP2773349A1 (en) | 2011-11-02 | 2014-09-10 | Vertex Pharmaceuticals Incorporated | Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases |
US20140127901A1 (en) | 2012-11-08 | 2014-05-08 | Taiwan Semiconductor Manufacturing Company, Ltd. | Low-k damage free integration scheme for copper interconnects |
IN2014KN00885A (sl) * | 2011-11-08 | 2015-10-02 | Vertex Pharma | |
SG10201606135TA (en) | 2012-01-25 | 2016-09-29 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
CN104470518A (zh) | 2012-02-27 | 2015-03-25 | ę²ę³°å ęÆčÆē©č”份ęéå ¬åø | čÆē©ē»åē©åå ¶ę½ēØ |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
EP2858645A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
US9012496B2 (en) | 2012-07-16 | 2015-04-21 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
JP6302923B2 (ja) | 2012-11-02 | 2018-03-28 | ćć¼ćććÆć¹ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗ ć¤ć³ć³ć¼ćć¬ć¤ćććļ¼¶ļ½ ļ½ļ½ļ½ ļ½ ļ¼°ļ½ļ½ļ½ļ½ļ½ļ½ļ½ ļ½ļ½ļ½ļ½ļ½ļ½ļ½ ļ¼©ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ ļ½ | ļ¼£ļ½ļ½ļ½ćåŖä»ććē¾ę£ć®å¦ē½®ć®ććć®å»č¬ēµęē© |
US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
US20160151335A1 (en) | 2013-06-26 | 2016-06-02 | Proteostasis Therapeutics, Inc. | Methods of modulating cftr activity |
RU2016122882A (ru) | 2013-11-12 | 2017-12-19 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | Š”ŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃŃŠµŠ½ŠøŃ ŃŠ°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠµŃŠŗŠøŃ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøŃŠøŠ¹ Š“Š»Ń Š»ŠµŃŠµŠ½ŠøŃ Š¾ŠæŠ¾ŃŃŠµŠ“Š¾Š²Š°Š½Š½ŃŃ cftr Š·Š°Š±Š¾Š»ŠµŠ²Š°Š½ŠøŠ¹ |
BR112016013164B1 (pt) | 2013-12-27 | 2022-07-26 | Chugai Seiyaku Kabushiki Kaisha | PreparaƧƵes sĆ³lidas contendo tofoglifozina e processos para produzir a mesma |
ES2957761T3 (es) | 2014-04-15 | 2024-01-25 | Vertex Pharma | Composiciones farmacĆ©uticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quĆstica |
RU2020134082A (ru) | 2014-10-06 | 2020-11-27 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | ŠŠ¾Š“ŃŠ»ŃŃŠ¾ŃŃ ŃŠµŠ³ŃŠ»ŃŃŠ¾ŃŠ° ŃŃŠ°Š½ŃŠ¼ŠµŠ¼Š±ŃŠ°Š½Š½Š¾Š¹ ŠæŃŠ¾Š²Š¾Š“ŠøŠ¼Š¾ŃŃŠø ŠæŃŠø Š¼ŃŠŗŠ¾Š²ŠøŃŃŠøŠ“Š¾Š·Šµ |
JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | ćć¼ćććÆć¹ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗ ć¤ć³ć³ć¼ćć¬ć¤ćććļ¼¶ļ½ ļ½ļ½ļ½ ļ½ ļ¼°ļ½ļ½ļ½ļ½ļ½ļ½ļ½ ļ½ļ½ļ½ļ½ļ½ļ½ļ½ ļ¼©ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ ļ½ | å¢čę§ē·ē¶ēčč²«éć³ć³ććÆćæć³ć¹å¶å¾”å åć®ć¢ćøć„ć¬ć¼ćæć¼ć®å ±ēµę¶ |
RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | ŠŠµŃŃŠµŠŗŃ Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š· ŠŠ½ŠŗŠ¾ŃŠæŠ¾ŃŠµŠ¹ŃŠµŠ“ | Š”ŠæŠ¾ŃŠ¾Š± ŠæŃŠ¾Š²ŠµŠ“ŠµŠ½ŠøŃ Š²ŃŃŠ¾ŠŗŠ¾ŠæŃŠ¾ŠøŠ·Š²Š¾Š“ŠøŃŠµŠ»ŃŠ½Š¾Š¹ ŃŠµŃŃŠ¾Š²Š¾Š¹ Š²ŃŃŠ¾ŠŗŠ¾ŃŃŃŠµŠŗŃŠøŠ²Š½Š¾Š¹ Š¶ŠøŠ“ŠŗŠ¾ŃŃŠ½Š¾Š¹ Ń ŃŠ¾Š¼Š°ŃŠ¾Š³ŃŠ°ŃŠøŠø |
MA41031A (fr) | 2014-11-26 | 2017-10-03 | Catabasis Pharmaceuticals Inc | ConjuguƩs cystƩamine-acide gras et leur utilisation comme activateurs de l'autophagie |
WO2016086136A1 (en) | 2014-11-26 | 2016-06-02 | Catabasis Pharmaceuticals, Inc. | Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders |
WO2016160945A1 (en) | 2015-03-31 | 2016-10-06 | Concert Pharmaceuticals, Inc. | Deuterated vx-661 |
WO2018183367A1 (en) | 2017-03-28 | 2018-10-04 | Van Goor Fredrick F | Methods of treating cystic fibrosis in patients with residual function mutations |
-
2007
- 2007-04-09 EP EP07755298.2A patent/EP2007756B1/en active Active
- 2007-04-09 RU RU2008144124/04A patent/RU2451018C2/ru active
- 2007-04-09 PL PL17209175T patent/PL3327016T3/pl unknown
- 2007-04-09 HU HUE16155334A patent/HUE036165T2/hu unknown
- 2007-04-09 NZ NZ596889A patent/NZ596889A/xx unknown
- 2007-04-09 IN IN2423KON2014 patent/IN2014KN02423A/en unknown
- 2007-04-09 HU HUE13167785A patent/HUE027630T2/en unknown
- 2007-04-09 HU HUE07755298A patent/HUE026145T2/en unknown
- 2007-04-09 SI SI200732178T patent/SI3327016T1/sl unknown
- 2007-04-09 EP EP13167785.8A patent/EP2674428B1/en active Active
- 2007-04-09 SI SI200731780A patent/SI2674428T1/sl unknown
- 2007-04-09 SI SI200732005T patent/SI3091011T1/sl unknown
- 2007-04-09 CA CA2869945A patent/CA2869945C/en active Active
- 2007-04-09 MX MX2008012945A patent/MX2008012945A/es active IP Right Grant
- 2007-04-09 ES ES17209175T patent/ES2882684T3/es active Active
- 2007-04-09 WO PCT/US2007/008975 patent/WO2007117715A2/en active Application Filing
- 2007-04-09 NZ NZ571803A patent/NZ571803A/en unknown
- 2007-04-09 BR BRPI0710965A patent/BRPI0710965B8/pt active IP Right Grant
- 2007-04-09 NZ NZ61148507A patent/NZ611485A/en unknown
- 2007-04-09 EP EP21156114.7A patent/EP3882245A1/en active Pending
- 2007-04-09 DK DK07755298.2T patent/DK2007756T3/en active
- 2007-04-09 CA CA2648719A patent/CA2648719C/en active Active
- 2007-04-09 PL PL16155334T patent/PL3091011T3/pl unknown
- 2007-04-09 PT PT131677858T patent/PT2674428T/pt unknown
- 2007-04-09 US US11/786,001 patent/US7776905B2/en active Active
- 2007-04-09 EP EP17209175.3A patent/EP3327016B1/en active Active
- 2007-04-09 SI SI200731695T patent/SI2007756T1/sl unknown
- 2007-04-09 CN CNA2007800210737A patent/CN101460489A/zh active Pending
- 2007-04-09 CN CN2013100749078A patent/CN103254177A/zh active Pending
- 2007-04-09 PL PL13167785T patent/PL2674428T3/pl unknown
- 2007-04-09 ES ES16155334.2T patent/ES2659364T3/es active Active
- 2007-04-09 HU HUE17209175A patent/HUE055205T2/hu unknown
- 2007-04-09 PL PL07755298T patent/PL2007756T3/pl unknown
- 2007-04-09 DK DK16155334.2T patent/DK3091011T3/en active
- 2007-04-09 AU AU2007235260A patent/AU2007235260B2/en active Active
- 2007-04-09 DK DK13167785.8T patent/DK2674428T3/en active
- 2007-04-09 PT PT161553342T patent/PT3091011T/pt unknown
- 2007-04-09 ES ES13167785.8T patent/ES2580803T3/es active Active
- 2007-04-09 ES ES07755298.2T patent/ES2554353T3/es active Active
- 2007-04-09 JP JP2009504359A patent/JP5420395B2/ja active Active
- 2007-04-09 LT LTEP16155334.2T patent/LT3091011T/lt unknown
- 2007-04-09 EP EP16155334.2A patent/EP3091011B1/en active Active
- 2007-04-09 PT PT77552982T patent/PT2007756E/pt unknown
-
2008
- 2008-10-06 IL IL194576A patent/IL194576A/en active IP Right Grant
- 2008-10-29 ZA ZA200809290A patent/ZA200809290B/xx unknown
-
2010
- 2010-07-02 US US12/829,879 patent/US8598181B2/en active Active
-
2013
- 2013-10-21 US US14/058,839 patent/US8912199B2/en active Active
- 2013-11-20 JP JP2013240205A patent/JP5827297B2/ja active Active
-
2014
- 2014-11-04 US US14/532,791 patent/US20150119441A1/en not_active Abandoned
-
2015
- 2015-03-31 JP JP2015073706A patent/JP2015120762A/ja active Pending
- 2015-11-25 CY CY20151101060T patent/CY1116979T1/el unknown
-
2016
- 2016-05-24 US US15/162,887 patent/US9758510B2/en active Active
- 2016-07-05 CY CY20161100628T patent/CY1117731T1/el unknown
-
2017
- 2017-07-26 US US15/659,926 patent/US10239867B2/en active Active
-
2018
- 2018-03-19 CY CY20181100319T patent/CY1120045T1/el unknown
-
2019
- 2019-02-15 US US16/276,887 patent/US10975061B2/en active Active
-
2021
- 2021-02-22 US US17/181,931 patent/US11639347B2/en active Active
-
2023
- 2023-02-10 US US18/108,053 patent/US20240092766A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014KN02423A (sl) | ||
MX357497B (es) | Moduladores de transportadores de casete de union a atp. | |
HK1138586A1 (en) | Modulators of cftr cftr | |
WO2010054138A3 (en) | Modulators of atp-binding cassette transporters | |
HK1140475A1 (en) | Azaindole derivatives as cftr modulators | |
WO2009038913A3 (en) | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | |
HK1148006A1 (en) | Isoquinoline modulators of atp-binding cassette transporters atp | |
WO2006099256A3 (en) | Modulators of atp-binding cassette transporters | |
NZ583878A (en) | Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR) | |
AU2010327993A8 (en) | 4-oxo-1H-quinoline-3-carboxamides as modulators of ATP-Binding cassette transporters | |
WO2007044560A3 (en) | Modulators of atp-binding cassette transporters | |
MX357328B (es) | Moduladores de trasportadores de casete enlazante de atp. | |
MX365890B (es) | Moduladores de transportadores con casete de uniĆ³n con atp. | |
WO2006127588A3 (en) | Modulators of atp-binding cassette transporters | |
WO2009108657A3 (en) | Heteroaryl derivatives as cftr modulators | |
NO20082674L (no) | Heterocykliske modulatorer for ATP-bindende kassett-transportere | |
MX2008002019A (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. | |
DE602004022819D1 (de) | Von atp-bindende kassette transportern | |
WO2005026137A3 (en) | Modulators of atp-binding cassette transporters | |
HK1092353A1 (en) | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters | |
NZ586271A (en) | Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator | |
EP2502913A3 (en) | Modulators of ATP-binding cassette transporters |